NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,200 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
If your shares are held in street name (by your broker), you must notify the securities firm holding your stock. If you hold stock certificates in your name, address changes should be submitted in writing by U.S. Mail to our transfer agent: American Stock Transfer, 6201 15th Avenue, Brooklyn, NY 11219. Telephone: (800) 937-5449 and (718) 921-8124.
If you hold stock certificates in your name, please contact our transfer agent regarding the replacement of lost certificates: American Stock Transfer, 6201 15th Avenue, Brooklyn, NY 11219. Telephone: (800) 937-5449 and (718) 921-8124.